**SUPPLEMENTAL TABLE 1.** Eight phase 3 studies included in the analysis

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Study number** | **Study objective** | **Study design** | **Treatment arms** | **Study, N\*** | **Duration** |
|
| 3061NCT00072774 | Efficacy, safety in MDD  | Randomized DB, placebo-controlled, fixed dose | Desvenlafaxine 100 mgDesvenlafaxine 200 mgDesvenlafaxine 400 mgPlacebo | 470 | 8 weeks |
| 3322NCT00277823 | Efficacy, safety in MDD | Randomized DB, placebo-controlled, fixed dose | Desvenlafaxine 50 mg/dDesvenlafaxine 100 mg/dPlacebo | 451 | 8 weeks |
| 3333NCT00300378 | Efficacy, safety in MDD | Randomized DB, placebo-controlled, fixed dose | Desvenlafaxine 50 mg/dDesvenlafaxine 100 mg/dPlacebo | 485 | 8 weeks |
| 3354NCT00384033 | Efficacy, safety in MDD | Randomized, DB, placebo- and, comparator-controlled, fixed-dose | Desvenlafaxine 50 mg/dDesvenlafaxine 100 mg/dDuloxetine 60 mg/dPlacebo | 616 | 8 weeks |
| 33595NCT00798707 | Efficacy, safety in MDD | Randomized, DB, placebo-controlled, fixed-dose | Desvenlafaxine 25 mg/dDesvenlafaxine 50 mg/dPlacebo | 699 | 8 weeks |
| 33626NCT00863798 | Efficacy, safety in MDD | Randomized, DB, placebo-controlled, fixed-dose | Desvenlafaxine 10 mg/dDesvenlafaxine 50 mg/dPlacebo | 673 | 8 weeks |
| 33647NCT01121484 | Efficacy, safety in MDD; perimenopausal and postmenopausal women | Randomized, DB, placebo-controlled, fixed-dose | Desvenlafaxine 50 mg/dPlacebo | 434 | 10 weeks (8-week primary endpoint) |
| 44158NCT00824291 | Efficacy, safety in MDD; functional outcomes in employed patients | Randomized, DB, placebo-controlled, fixed-dose | Desvenlafaxine 50 mg/dPlacebo | 427 | 12 weeks |

DB = double-blind; MDD = major depressive disorder; OL = open-label.

\*Total number of patients in the safety population (all randomized patients who took at least 1 dose of study medication).

**References**

1. DeMartinis NA, Yeung PP, Entsuah R, Manley AL. A double-blind, placebo-controlled study of the efficacy and safety of desvenlafaxine succinate in the treatment of major depressive disorder. *J Clin Psychiatry.* 2007;68(5):677-688.

2. Liebowitz MR, Manley AL, Padmanabhan SK, Ganguly R, Tummala R, Tourian KA. Efficacy, safety, and tolerability of desvenlafaxine 50 mg/day and 100 mg/day in outpatients with major depressive disorder. *Curr Med Res Opin.* 2008;24(7):1877-1890.

3. Boyer P, Montgomery S, Lepola U, et al. Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial. *Int Clin Psychopharmacol.* 2008;23(5):243-253.

4. Tourian KA, Padmanabhan SK, Groark J, Brisard C, Farrington D. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies. *Clin Ther.* 2009;31 Pt 1:1405-1423.

5. Iwata N, Tourian KA, Hwang E, Mele L, Vialet C, for the Study 3359 investigators. Efficacy and safety of desvenlafaxine 25 and 50 mg/day in a randomized, placebo-controlled study of depressed outpatients. *J Psychiatr Pract.* 2013;19(1):5-14.

6. Liebowitz MR, Tourian KA, Hwang E, Mele L, for the Study 3362 investigators. A double-blind, randomized, placebo-controlled study assessing the efficacy and tolerability of desvenlafaxine 10 and 50 mg/d in adult outpatients with major depressive disorder. *BMC Psychiatry.* 2013;13(1):94.

7. Clayton AH, Kornstein SG, Dunlop BW, et al. Efficacy and safety of desvenlafaxine 50 mg/d in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder. *J Clin Psychiatry.* 2013;74(10):1010-1017.

8. Dunlop BW, Reddy S, Yang L, Lubaczewski S, Focht K, Guico-Pabia CJ. Symptomatic and functional improvement in employed depressed patients: a double-blind clinical trial of desvenlafaxine versus placebo. *J Clin Psychopharmacol.* 2011;31(5):569-576.